Clene Q2 net loss $13.4M; NDA for CNM-Au8 in ALS expected early Q4 2026

Clene Inc.

NDA for CNM-Au8 in ALS under accelerated approval expected early Q4 2026; FDA confirmed data may support submission.
Cash $9.7M at June 30 vs $5.2M at Dec 31; runway through late Q4 2026.
Net loss $13.4M ($1.08/share) vs $7.4M ($0.78) in Q2 2025; other expense $8.1M on warrant/derivative fair value.
R&D flat at $3.5M; G&A down to $1.9M from $2.4M.
Closed $7M offering; extended convertible debt maturities to Aug 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.